Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 2/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14363239 | 0.87 | FKBP1A (0.32) | FKBP1A | |
| SCHEMBL4057283 | 0.86 | FKBP1A (0.32) | FKBP1A | |
| SCHEMBL17616831 | 0.82 | MAPK1 (0.42) | MAPK1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL17616835 | 0.77 | MAPK1 (0.41) | MAPK1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL8062803 | 0.77 | FKBP1A (0.33) | FKBP1A | |
| SCHEMBL12632024 | 0.77 | FKBP1A (0.33) | FKBP1A | |
| SCHEMBL7334111 | 0.76 | TOP2A (0.32) | — | |
| SCHEMBL23763372 | 0.74 | MAPK1 (0.39) | MAPK1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL1856899 | 0.74 | HTT (0.37) | MAPK1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL8749243 | 0.74 | MAPK1 (0.39) | MAPK1CDK1CCNB1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296946-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Atrium Therapeutics, Inc. | 2025-09-25 | — | — | US | disclosed |
| US-12365704-B2 | Nucleic acid-polypeptide compositions and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20230234978-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Atrium Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11578090-B2 | Nucleic acid-polypeptide compositions and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| EP-3980436-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Avidity Biosciences, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| US-20200385414-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Atrium Therapeutics, Inc. | 2020-12-10 | — | — | US | disclosed |
| WO-2020247782-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| US-7427678-B2 | Method for immobilizing oligonucleotides employing the cycloaddition bioconjugation method | SIGMA-ALDRICH CO. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20030215801-A1 | Method for immobilizing oligonucleotides employing the cycloaddition bioconjugation method | SIGMA-ALDRICH CO., LLC | 2003-11-20 | — | — | US | disclosed |
| EP-1287404-A4 | METHOD FOR IMMOBILIZING OLIGONUCLEOTIDES EMPLOYING THE CYCLOADDITION BIOCONJUGATION METHOD | PROLIGO LLC (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-1287404-A1 | METHOD FOR IMMOBILIZING OLIGONUCLEOTIDES EMPLOYING THE CYCLOADDITION BIOCONJUGATION METHOD | Proligo LLC (US) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001084234-A1 | METHOD FOR IMMOBILIZING OLIGONUCLEOTIDES EMPLOYING THE CYCLOADDITION BIOCONJUGATION METHOD | PROLIGO LLC (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365704-B2 | Nucleic acid-polypeptide compositions and uses thereof | POLM, POLN, POLI | MAPK1 4321/4885CDK1 3332/4885CCNB1 1773/4885 |
| US-20200385414-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | POLM, POLN, POLI | MAPK1 4321/4885CDK1 3332/4885CCNB1 1773/4885 |
| US-11578090-B2 | Nucleic acid-polypeptide compositions and uses thereof | POLM, POLN, POLI | MAPK1 4321/4885CDK1 3332/4885CCNB1 1773/4885 |
| US-20230234978-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | POLM, POLN, POLI | MAPK1 4321/4885CDK1 3332/4885CCNB1 1773/4885 |
| US-20250296946-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | POLM, POLN, POLI | MAPK1 4321/4885CDK1 3332/4885CCNB1 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.